Premium
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials
Author(s) -
Iwatsubo Takeshi,
Iwata Atsushi,
Suzuki Kazushi,
Ihara Ryoko,
Arai Hiroyuki,
Ishii Kenji,
Senda Michio,
Ito Kengo,
Ikeuchi Takeshi,
Kuwano Ryozo,
Matsuda Hiroshi,
Sun ChungKai,
Beckett Laurel A.,
Petersen Ronald C.,
Weiner Michael W.,
Aisen Paul S.,
Donohue Michael C.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.03.009
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , cognitive impairment , cognition , alzheimer's disease , amyloid (mycology) , medicine , neuroscience , disease , psychology , pathology
We conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America. Methods A total of 537 Japanese subjects with normal cognition, late amnestic mild cognitive impairment (LMCI), or mild Alzheimer's disease (AD) were enrolled using the same criteria as ADNI. Rates of changes in representative cognitive or functional measures were compared for amyloid positron emission tomography‐ or cerebrospinal fluid amyloid β(1–42)‐positive LMCI and mild AD between J‐ADNI and ADNI. Results Amyloid positivity rates were significantly higher in normal cognition of ADNI but at similar levels in LMCI and mild AD between J‐ADNI and ADNI. Profiles of decline in cognitive or functional measures in amyloid‐positive LMCI in J‐ADNI (n = 75) and ADNI (n = 269) were remarkably similar, whereas those in mild AD were milder in J‐ADNI (n = 73) compared with ADNI (n = 230). Discussion These results support the feasibility of bridging of clinical trials in the prodromal stage of AD between Asia and western countries.